TheraRadar
Clinical-Stage Companies / Valenta Pharm JSC

Valenta Pharm JSC

Pre-Approval PRO BETA
30
Total Trials
12
Phase 3
5
Phase 2
12
Recruiting
275
Score

Pipeline by Phase

Phase 3
12
Phase 2
5
Phase 1
10

Therapeutic Focus

Common Cold Influenza, Human Acute Respiratory Infection Influenza Biliary Dyskinesia

Clinical Trials (30)

NCT07595003 Phase 3 RECRUITING

Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Chronic Cholecystitis and Biliary Dyskinesia

Started: 12/12/2025

NCT05544916 Phase 3 COMPLETED

A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

Started: 8/5/2022

NCT05561816 Phase 3 COMPLETED

Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma

Started: 7/19/2022

NCT05586789 Phase 3 COMPLETED

A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustment Disorders

Started: 10/12/2022

NCT05269290 Phase 3 COMPLETED

Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections

Started: 9/23/2021

NCT05216497 Phase 3 COMPLETED

Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19

Started: 10/6/2021

NCT05273619 Phase 3 COMPLETED

Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection

Started: 5/23/2022

NCT05430217 Phase 3 COMPLETED

Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo

Started: 1/28/2022

NCT03206346 Phase 3 COMPLETED

Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.

Started: 1/1/2012

NCT03191097 Phase 3 COMPLETED

Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.

Started: 8/1/2014

NCT03189537 Phase 3 COMPLETED

Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections

Started: 10/3/2010

NCT02644018 Phase 3 COMPLETED

Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.

Started: 1/1/2016

NCT07420985 Phase 2 RECRUITING

Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.

Started: 10/24/2025

NCT06842966 Phase 2 RECRUITING

Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia

Started: 10/17/2024

NCT06843018 Phase 2 RECRUITING

Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment of Acute Infectious and Inflammatory Pharyngeal Diseases Compared With Drug Septolete Total, Lozenges

Started: 11/14/2024

NCT05030324 Phase 2 COMPLETED

A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute Viral Upper Respiratory Infections

Started: 10/1/2021

NCT05269329 Phase 2 COMPLETED

Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection

Started: 4/26/2021

NCT07421011 Phase 1 RECRUITING

Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.

Started: 11/6/2025

NCT06859281 Phase 1 RECRUITING

Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers

Started: 12/10/2024

NCT06857890 Phase 1 RECRUITING

Safety, Tolerability, and Pharmacokinetic Profile of Grammidin With Anesthetic, a Metered Dose Topical Spray in Healthy Volunteers

Started: 12/9/2024

NCT06859333 Phase 1 RECRUITING

Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules, Folliwing Single and Subsequent Multiple Oral Administration in Healthy Volunteers

Started: 1/13/2025

NCT07594977 Phase 1 RECRUITING

Food-Effect, Single and Multiple Dose Pharmacokinetics, Safety and Tolerability Study of 4-MUST, 128 mg, Tablets in Healthy Volunteers

Started: 1/26/2026

NCT07645534 Phase 1 RECRUITING

Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.

Started: 7/11/2025

NCT06342778 Phase 1 COMPLETED

Pharmacokinetics and Bioequivalence of Doxylamine+Pyridoxine and Diclectin Under Fed Conditions in Healthy Volunteers

Started: 2/27/2024

NCT05505097 Phase 1 COMPLETED

Safety and Pharmacokinetics of Dioxidin, Solution for Topical and External Use, 0.25 mg/ml and Dioxidin, Solution for Infusion and External Use, 5 mg/ml in Healthy Volunteers

Started: 5/4/2022

NCT05294250 Phase 1 COMPLETED

Study of the Effect of Food Intake on the Bioavailability of XC8 10 mg Film-coated Tablets

Started: 2/1/2022

NCT05295121 Phase 1 COMPLETED

Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets

Started: 2/10/2022

NCT06843044 Phase 4 RECRUITING

Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders

Started: 1/13/2025

NCT06321341 Phase 4 RECRUITING

Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo

Started: 1/24/2024

NCT03154515 Phase 4 COMPLETED

Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults

Started: 1/1/2010

Drug Candidates

Trimedat® Ingavirin Forte, 90 mg + 5 mg, Capsules Ingavirin Forte, 90 mg + 10 mg, Capsules Ingavirin Forte, 90 mg + 20 mg, Capsules Ingavirin, 90 mg, Capsules 4-MUST Doxylamine + Pyridoxine Diclectin Grammidin neo Grammidin, a metered dose topical spray
Activity Status: Active
Last Trial Started: 1/26/2026
Last Trial Ended: 5/2/2024
Trials (12 months): 5
Completed Trials: 18
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.